Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Paola RoaValentina FoglizzoGuilherme HaradaMatteo RepettoAmanda KulickElisa de StanchinaMichelle de MarchenaSupipi AuwardtShaza Sayed AhmedNicole Virginia BremerSoo-Ryum YangYangbo FengChao ZhouNorman KongRuixia LiangHaipeng XuBin ZhangAlberto BardelliEneda ToskaAndrea VenturaAlexander E DrilonEmiliano CoccoPublished in: British journal of cancer (2024)
Our data identifies zurletrectinib as a novel, highly potent next-generation TRK inhibitor with stronger in vivo brain penetration and intracranial activity than other next-generation agents.